


Attorney Docket No. 5776.204-US  
Hansen et al.  
Serial No. 09/872,127 Filed June 1, 2001  
Via facsimile to: 571-273-0571

## CLAIM LISTING

1. (Currently amended) A method for ~~treating a condition related to~~  
angiogenesis reducing angiogenesis or neovascularization, said method  
comprising administering to a patient in need of such ~~treatment~~ method an effective  
amount of a compound having the general formula Ia



wherein  $R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy, hydroxy,  $NR^7R^8$ , cyano, methylthio or  $-SO_2NR^7R^8$  wherein  $R^7$  and  $R^8$  independently are hydrogen or  $C_{1-6}$ -alkyl; and

Y is  $>\underline{N}-CH_2-$ ,  $>\underline{CH}-CH_2-$  or  $>\underline{C}=\underline{CH}-$  wherein only the underscored atom participates in the ring system; or

Y is  $-\underline{CH}_2\underline{N}(-)CH_2-$ ,  $-CH_2\underline{N}(-)\underline{CH}_2-$ ,  $-(\underline{C}=\underline{O})\underline{N}(-)CH_2-$ ,  $-CH_2\underline{N}(-)(\underline{C}=\underline{O})-$ ,  $-\underline{CH}_2\underline{CH}(-)CH_2-$ ,  $-CH_2\underline{CH}(-)\underline{CH}_2-$ ,  $-\underline{CH}_2\underline{C}(-)=CH-$ ,  $-CH=\underline{C}(-)\underline{CH}_2-$ ,  $-\underline{OCH}(-)CH_2-$ ,  $-CH_2\underline{CH}(-)\underline{O}-$ ,  $-\underline{SCH}(-)CH_2-$ ,  $-CH_2\underline{CH}(-)\underline{S}-$ , wherein only the underscored atom participates in the ring system; or

Y is  $>\underline{N}-$ ,  $>\underline{CH}-$ ,  $>\underline{N}-(\underline{C}=\underline{O})-$  or  $>\underline{C}=\underline{C}(R^8)-$ , wherein only the underscored atom participates in the ring system and  $R^8$  is hydrogen or  $C_{1-6}$ -alkyl; or

Y is  $>\underline{CH}-O-$  or  $>\underline{CH}-S(O)_y$  wherein y is 0, 1 or 2, or  $-N(R^8)-$  wherein  $R^8$  is hydrogen or  $C_{1-6}$ -alkyl, and wherein only the underscored atom participates in the ring system; and

X is completion of an optional bond, ortho-phenylene,  $-O-$ ,  $-S-$ ,  $-C(R^7R^8)-$ ,  $-CH_2CH_2-$ ,  $-CH=CH-CH_2-$ ,  $-CH_2-CH=CH-$ ,  $-CH_2-(C=O)-$ ,  $-(C=O)-CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH=CH-$ ,  $-N(R^8)-$ ,  $-(C=O)-$ ,  $-(C=O)-N(R^8)-$ ,  $-O-CH_2-$ ,  $-CH_2-O-$ ,  $-OCH_2O-$ ,  $-CH_2OCH_2-$ ,  $-S-CH_2-$ ,  $-CH_2-S-$ ,  $-(CH_2)N(R^8)-$ ,  $-N(R^8)(CH_2)-$ ,  $-N(CH_3)SO_2-$ ,  $-SO_2N(CH_3)-$ ,  $-CH(R^9)CH_2-$ ,  $-CH_2CH(R^9)-$ ,  $-(C=O)-$

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

, -N(R<sup>8</sup>)- or -(S=O)- wherein R<sup>7</sup> and R<sup>8</sup> independently are hydrogen or C<sub>1-6</sub>-alkyl; and wherein R<sup>9</sup> is C<sub>1-6</sub>-alkyl or phenyl; and

p and q independently are 0 or 1; and

r is 0, 1, 2, 3 or 4; and


Z is selected from



wherein R<sup>6</sup> is OH or C<sub>1-6</sub>-alkoxy; and

.... is optionally a single bond or a double bond; or

Z is selected from



wherein n is 1 or 2;

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

$R^3$  is  $-(CH_2)_mOH$  or  $-(CH_2)_sCOR^4$  wherein  $m$  is 0, 1, 2, 3, 4, 5 or 6 and  $s$  is 0 or 1 and wherein

$R^4$  is  $-OH$ ,  $-NH_2$ ,  $-NHOH$  or  $C_{1-6}$ -alkoxy; and


$R^5$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$R^{10}$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$R^{11}$  is hydrogen or  $C_{1-6}$ -alkyl; and

$\dots$  is optionally a single bond or a double bond; or

$Z$  is selected from



wherein  $u$  is 0 or 1;

$R^3$  is  $-(CH_2)_mOH$  or  $-(CH_2)_sCOR^4$  wherein  $m$  is 0, 1, 2, 3, 4, 5 or 6 and  $s$  is 0 or 1 and wherein

$R^4$  is  $-OH$ ,  $-NH_2$ ,  $-NHOH$  or  $C_{1-6}$ -alkoxy; and

$R^5$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$R^{10a}$  is hydrogen or  $C_{1-6}$ -alkyl; and

$A$  is  $C_{1-6}$ -alkylene,  $C_{2-6}$ -alkenylene or  $C_{2-6}$ -alkynylene; or


$Z$  is selected from

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571




wherein  $M_1$  and  $M_2$  independently are C or N; and

$R^{35}$  is hydrogen,  $C_{1-6}$ -alkyl, phenyl or benzyl; and

$R^{33}$  is hydrogen, halogen, trifluoromethyl, nitro or cyano; and


$R^{34}$  is hydrogen, halogen, trifluoromethyl, nitro, cyano,  $-(CH_2)_wCOR^{31}$ ,  $-(CH_2)_wOH$  or  $-(CH_2)_wSO_2R^{31}$  wherein  $R^{31}$  is hydroxy,  $C_{1-6}$ -alkoxy or  $NHR^{32}$ , wherein  $R^{32}$  is hydrogen or  $C_{1-6}$ -alkyl, and  $w$  is 0, 1 or 2; or

$R^{34}$  is selected from



; or

Z is



wherein  $b$  is 0, 1, 2, 3 or 4; and

Attorney Docket No. 5776.204-US


Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

B is  $-\text{CH}=\text{CR}^{49}-$ ,  $-\text{CR}^{49}=\text{CH}-$ ,  $-\text{C}\equiv\text{C}-$ ,  $-(\text{C}=\text{O})-$ ,  $-(\text{C}=\text{CH}_2)-$ ,  $-(\text{CR}^{49}\text{R}^{40})-$ ,  $-\text{CH}(\text{OR}^{41})-$ ,  $-\text{CH}(\text{NHR}^{41})-$ , phenylene,  $\text{C}_{3-7}$ -cycloalkylene or the completion of a bond, wherein  $\text{R}^{49}$  and  $\text{R}^{40}$  independently are hydrogen,  $\text{C}_{1-6}$ -unbranched alkyl,  $\text{C}_{3-6}$ -branched alkyl or  $\text{C}_{3-7}$ -cycloalkyl and wherein  $\text{R}^{41}$  is hydrogen or  $\text{C}_{1-6}$ -alkyl; and

U is



wherein  $\text{R}^{42}$  is hydrogen,  $-(\text{CH}_2)_c\text{OH}$  or  $-(\text{CH}_2)_d\text{COR}^{47}$  wherein c is 0, 1, 2, 3, 4, 5 or 6 and d is 0 or 1 and wherein  $\text{R}^{47}$  is  $-\text{OH}$ ,  $-\text{NHR}^{44}$  or  $\text{C}_{1-6}$ -alkoxy wherein  $\text{R}^{44}$  is hydrogen or  $\text{C}_{1-6}$ -alkyl; and

$\text{R}^{43}$  is cyano,  $-\text{NR}^{45}\text{R}^{47}$ ,  $-\text{NR}^{45}-\text{V}$  or  $-(\text{CHR}^{48})_e-\text{V}$  wherein  $\text{R}^{45}$  and  $\text{R}^{47}$  independently are hydrogen or  $\text{C}_{1-6}$ -alkyl and wherein e is 0, 1, 2, 3, 4, 5 or 6 and wherein  $\text{R}^{48}$  is hydrogen, halogen, cyano, trifluoromethyl, hydroxy,  $\text{C}_{1-6}$ -alkyl,  $\text{C}_{1-6}$ -alkoxy,  $-\text{NR}^{45}\text{R}^{47}$  or  $-\text{COOH}$ , and wherein V is  $\text{C}_{3-8}$ -cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more halogen, cyano, trifluoromethyl, hydroxy, methylthio,  $\text{C}_{1-6}$ -alkyl or  $\text{C}_{1-6}$ -alkoxy; or


U is selected from

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571



wherein  $g$  is 0, 1 or 2; and

$R^{11u}$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$R^{12u}$  is  $-(CH_2)_hOH$  or  $-(CH_2)_jCOR^{17u}$  wherein  $h$  is 0, 1, 2, 3, 4, 5 or 6 and  $j$  is 0 or 1 and wherein  $R^{17u}$  is  $-OH$ ,  $-NHR^{20u}$  or  $C_{1-6}$ -alkoxy wherein  $R^{20u}$  is hydrogen or  $C_{1-6}$ -alkyl; and



$R^{13u}$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

Attorney Docket No. 5776.204-US

Hansen et al.


Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

 $R^{14u}$  is hydrogen or  $C_{1-6}$ -alkyl; andC is  $C_{1-6}$ -alkylene,  $C_{2-6}$ -alkenylene or  $C_{2-6}$ -alkynylene; and $\text{---}$  is optionally a single bond or a double bond; and $R^{18u}$  is selected fromwherein  $M_1$  and  $M_2$  independently are C or N; and $R^{19u}$  is hydrogen,  $C_{1-6}$ -alkyl, phenyl or benzyl; and $R^{15u}$  is hydrogen, halogen, trifluoromethyl, nitro or cyano; and $R^{16u}$  is hydrogen, halogen, trifluoromethyl, nitro, cyano,  $-(CH_2)_kCOR^{17u}$ ,  $-(CH_2)_kOH$  or  $-(CH_2)_kSO_2R^{17u}$  wherein k is 0, 1 or 2; or $R^{16u}$  is selected from

; or

Z is selected from



Attorney Docket No. 5776.204-US


Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

wherein  $R^{53}$  is  $-(CH_2)_{pp}COOH$  wherein  $pp$  is 2, 3, 4, 5 or 6; or

Z is



wherein  $tt$  and  $t$  independently are 0, 1 or 2; and


$R^{63}$  is H,  $C_{1-6}$ -alkyl or optionally substituted benzyl;

$R^{64}$  and  $R^{65}$  independently are H,  $C_{1-8}$ -alkyl,  $C_{3-7}$ -cycloalkyl, phenyl, thienyl, benzyl, or  $R^{64}$

and  $R^{65}$  together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring; and

$R^{66}$  is H or  $C_{1-6}$ -alkyl; or

Z is selected from



wherein D is  $-CH_2-$ ,  $-O-$ ,  $-S-$  or  $-N(R^7)-$  wherein  $R^7$  is hydrogen or  $C_{1-6}$ -alkyl; and

$R^{3m}$  is  $-(CH_2)_{mm}OH$  or  $-(CH_2)_{mp}COR^4$  wherein  $mm$  and  $mp$  are 1, 2, 3 or 4 and  $R^4$  is OH,  $NH_2$ ,  $NHOH$  or  $C_{1-6}$ -alkoxy; or

having the general formula Ib




Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571



(Ib)


wherein  $R^{1b}$  and  $R^{2b}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$R^{3b}$  is hydrogen or  $C_{1-3}$ -alkyl; and


$A_b$  is  $C_{1-3}$ -alkylene; and

$Y_b$  is  $>\underline{C}H-CH_2-$ ,  $>\underline{C}=CH-$ ,  $>\underline{C}H-O-$ ,  $>\underline{C}=N-$ ,  $>\underline{N}-CH_2-$  wherein only the underscored atom participates in the ring system; and

$Z_b$  is selected from



Attorney Docket No. 5776.204-US  
 Hansen et al.  
 Serial No. 09/872,127 Filed June 1, 2001  
 Via facsimile to: 571-273-0571



wherein nb is 1 or 2; and

$R^{11b}$  is hydrogen or  $C_{1-6}$ -alkyl; and

$R^{12b}$  is hydrogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or phenyl optionally substituted with halogen, trifluoro-methyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$R^{13b}$  is hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and

$R^{14b}$  is  $-(CH_2)_{mb}OH$  or  $-(CH_2)_{tb}COR^{15b}$  wherein mb is 0, 1, 2, 3, 4, 5 or 6 and tb is 0 or 1 and wherein  $R^{15b}$  is  $-OH$ ,  $NH_2$ ,  $-NHOH$  or  $C_{1-6}$ -alkoxy; and

$R^{16b}$  is  $C_{1-6}$ -alkyl or  $-B_b-COR^{15b}$ , wherein  $B_b$  is  $C_{1-6}$ -alkylene,  $C_{2-6}$ -alkenylene or  $C_{2-6}$ -alkynylene and  $R^{15b}$  is the same as above; and

... is optionally a single bond or a double bond; or


having the general formula Ic

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571



(Ic)


wherein  $R^{1c}$  and  $R^{2c}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy;

$X_c$  is ortho-phenylene, -O-, -S-,  $-C(R^{6c}R^{7c})-$ ,  $-CH_2CH_2-$ ,  $-CH=CH-CH_2-$ ,  $-CH_2-CH=CH-$ ,  $-CH_2-(C=O)-$ ,  $-(C=O)-CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH=CH-$ ,  $-N(R^{8c})-(C=O)-$ ,  $-(C=O)-N(R^{8c})-$ ,  $-O-CH_2-$ ,  $-CH_2-O-$ ,  $-OCH_2O-$ ,  $-S-CH_2-$ ,  $-CH_2-S-$ ,  $-(CH_2)N(R^{8c})-$ ,  $-N(R^{8c})(CH_2)-$ ,  $-N(CH_3)SO_2-$ ,  $-SO_2N(CH_3)-$ ,  $-CH(R^{10c})CH_2-$ ,  $-CH_2CH(R^{10c})-$ ,  $-(C=O)-$ ,  $-N(R^{9c})-$  or  $-(S=O)-$  wherein  $R^{6c}$ ,  $R^{7c}$ ,  $R^{8c}$  and  $R^{9c}$  independently are hydrogen or  $C_{1-6}$ -alkyl, and wherein  $R^{10c}$  is  $C_{1-6}$ -alkyl or phenyl;  $Y_c$  is C or N;

.... is optionally a single bond or a double bond, and .... is a single bond when  $Y_c$  is N;

$mc$  is 1, 2, 3, 4, 5 or 6; and


$Z_c$  is  $-COOR^{3c}$  or



wherein  $R^{3c}$  is H or  $C_{1-6}$ -alkyl; or

having the general formula Id

Attorney Docket No. 5776.204-US  
 Hansen et al.  
 Serial No. 09/872,127 Filed June 1, 2001  
 Via facsimile to: 571-273-0571



wherein  $R^{1d}$  and  $R^{2d}$  independently are hydrogen, halogen, trifluoromethyl, hydroxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and  
 $X_d$  is -O-, -S- or -S(=O)-; and  
 $rd$  is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and  
 $Z_d$  is selected from



wherein  $R^{3d}$  is  $-(CH_2)_{md}OH$  or  $-(CH_2)_{pd}COR^{4d}$  wherein  $md$  and  $pd$  independently are 0, 1, 2, 3 or 4 and  $R^{4d}$  is OH,  $NH_2$ ,  $NHOH$  or  $C_{1-6}$ -alkoxy; or  
 a pharmaceutically acceptable salt of any of the foregoing.

2. (Currently amended) The method according to claim 1 wherein the angiogenesis or neovascularization condition is related to reduction is for treatment of cancer.
3. (Currently amended) The method according to claim 1 wherein the angiogenesis or neovascularization is ocular condition is related to ocular neovascularization.
4. (Original) The method according to claim 1 wherein, in formula Ia,

Attorney Docket No. 5776.204-US  
Hansen et al.  
Serial No. 09/872,127 Filed June 1, 2001  
Via facsimile to: 571-273-0571

$R^1$ ,  $R^{1a}$ ,  $R^2$  and  $R^{2a}$  independently are hydrogen, halogen, trifluoromethyl,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy; and


Y is  $>\underline{N}$ -CH<sub>2</sub>-,  $>\underline{CH}$ -CH<sub>2</sub>- or  $>\underline{C}$ =CH- wherein only the underscored atom participates in the ring system; and

X is -O-, -S-, -C(R<sup>7</sup>R<sup>8</sup>)-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH=CH-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH=CH-, -N(R<sup>8</sup>)-(C=O)-, -O-CH<sub>2</sub>-, -(C=O)- or -(S=O)- wherein R<sup>7</sup> and R<sup>8</sup> independently are hydrogen or  $C_{1-6}$ -alkyl; and

p and q are 0, and

r is 1, 2 or 3; and

Z is selected from



wherein R<sup>6</sup> is OH or  $C_{1-6}$ -alkoxy; and

... is optionally a single bond or a double bond; and

a pharmaceutically acceptable salt of any of the foregoing.

5. (Original) The method according to claim 4 wherein the compound is selected from the group consisting of:

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

(R)-1-(3-(Fluoren-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(Thioxanthen-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-butyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10H-Phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-pyrrolidinacetic acid;

(R)-1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(2-Trifluoromethyl-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(5-Oxo-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-10-Oxa-5-aza-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

Attorney Docket No. 5776.204-US  
Hansen et al.  
Serial No. 09/872,127 Filed June 1, 2001  
Via facsimile to: 571-273-0571

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

(R)-1-(3-(6,7-Dihydro-5H-dibenzo[b,g]azocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10-Methyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9(H)-Oxo-10H-acridin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(2-(6,11-Dihydrodibenz[b,e]oxepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

Attorney Docket No. 5776.204-US  
Hansen et al.  
Serial No. 09/872,127 Filed June 1, 2001  
Via facsimile to: 571-273-0571

(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(Z)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(E)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride,

and a pharmaceutically acceptable salt of any of the foregoing.

6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Cancelled)
25. (Cancelled)
26. (Cancelled)
27. (Cancelled)
28. (Cancelled)
29. (Cancelled)
30. (Cancelled)
31. (Cancelled)
32. (Cancelled)



Attorney Docket No. 5776.204-US  
Hansen et al.  
Serial No. 09/872,127 Filed June 1, 2001  
Via facsimile to: 571-273-0571

33. (Cancelled)

34. (Currently amended) The method according to claim 1 wherein the ~~pharmaceutical composition~~ pharmaceutically acceptable salt is in a form suitable for oral administration.

Attorney Docket No. 5776.204-US  
Hansen et al.  
Serial No. 09/872,127 Filed June 1, 2001  
Via facsimile to: 571-273-0571

### RESPONSE

The Examiner states in the Office Action Summary that claims numbered 1-34 are pending in the application, claims 6-33 are withdrawn from consideration, claims numbered 1, 2, 4, 5 and 34 are rejected, and claim number 3 is objected to.

(1) The Examiner has rejected claim number 1, 2, 4, 5 and 34 under 35 U.S.C. §112, first paragraph, for failing to comply with the written description requirement. Specifically: the examiner states the specification, while being enabling for the specific cancer disclosed, does not reasonable provide enablement for the term "a condition related to angiogenesis" or "cancer".

Applicant has amended claims numbered 1, 2 and 3 to more clearly define the present invention. Applicant believes these amendments obviate the Examiner's rejection based on treatment of cancer and treatment of conditions related to angiogenesis.

Applicant respectfully requests reconsideration and withdrawal of the rejections under 35 U.S.C. §112, first paragraph.

(2) The Examiner has rejected claim number 1, 2, 4, 5 and 34 under 35 U.S.C. §103(a) as being unpatentable over the Jørgensen et al. WO 96/31497.

Applicant has amended claims numbered 1, 2 and 3 to more clearly define the present invention. Applicant believes these amendments obviate the Examiner's rejection based on treatment of cancer.

Applicant respectfully requests reconsideration and withdrawal of the rejections under 35 U.S.C. §103(a).

Applicant has amended claim 34 to correct antecedent basis.

In view of the above, Applicant respectfully submits all claims are in condition for allowance. *Applicant respectfully requests notification via an Advisory Action or telephone call if the Examiner deems the case is not in condition for allowance.*

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. Applicant respectfully requests that

Attorney Docket No. 5776.204-US  
Hansen et al.  
Serial No. 09/872,127 Filed June 1, 2001  
Via facsimile to: 571-273-0571

a timely Notice of Allowance be issued in this case.

Respectfully submitted,

Date: September 15, 2004



Rosemarie R. Wilk-Orescan  
Registration Number 45,220  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

**23650**

PATENT TRADEMARK OFFICE